Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
ADRA2A 150 NOREPINEPHRINE CHEMBL1437 agonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423, 18064417, 10742288, 11306720, 18680204, 9836297, 1980236
ADRA2A 150 ARIPIPRAZOLE CHEMBL1112 antagonist DrugBank 17848919
ADRA2A 150 DIPIVEFRIN CHEMBL1201262 agonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
ADRA2A 150 AMOXAPINE CHEMBL1113 antagonist DrugBank 9589848, 6086881
ADRA2A 150 APOMORPHINE CHEMBL53 agonist GuideToPharmacologyInteractions, DrugBank 18691132
ADRA2A 150 BENZPHETAMINE HYDROCHLORIDE CHEMBL3544906 agonist DrugBank 17139284, 17016423
ADRA2A 150 CARVEDILOL CHEMBL723 antagonist DrugBank 15306222
ADRA2A 150 METHAMPHETAMINE CHEMBL1201201 agonist TdgClinicalTrial, DrugBank 15955613, 12453616, 9551769
ADRA2A 150 PERICIAZINE CHEMBL251940 antagonist DrugBank 6149771
ADRA2A 150 CHEMBL609728 CHEMBL609728 DrugBank
ADRA2A 150 DROXIDOPA CHEMBL2103827 agonist ChemblInteractions, DrugBank 11306720, 21173850, 18680204
ADRA2A 150 XYLOMETAZOLINE CHEMBL312448 agonist DrugBank 20030735, 2868542
ADRA2A 150 OXYMETAZOLINE CHEMBL762 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ADRA2A 150 TRAZODONE CHEMBL621 TEND
ADRA2A 150 ASENAPINE (CHEMBL3187365) CHEMBL3187365 TdgClinicalTrial
ADRA2A 150 GUANFACINE HYDROCHLORIDE CHEMBL1200494 agonist ChemblInteractions, TTD
ADRA2A 150 PARDOPRUNOX CHEMBL2103832 TdgClinicalTrial
ADRA2A 150 5-(N-ETHYL-N-ISOPROPYL)AMILORIDE CHEMBL517986 allosteric modulator GuideToPharmacologyInteractions
ADRA2A 150 PIRIBEDIL (CHEMBL1371770) CHEMBL1371770 antagonist GuideToPharmacologyInteractions
ADRA2A 150 PRAZOSIN CHEMBL2 antagonist GuideToPharmacologyInteractions
ADRA2A 150 CHEMBL25554 CHEMBL25554 antagonist GuideToPharmacologyInteractions
ADRA2A 150 LABETALOL HYDROCHLORIDE CHEMBL1200323 antagonist ChemblInteractions
ADRA2A 150 DIPIVEFRIN HYDROCHLORIDE CHEMBL1200833 agonist ChemblInteractions
ADRA2A 150 MEPHENTERMINE SULFATE CHEMBL1200996 agonist ChemblInteractions
ADRA2A 150 ESMIRTAZAPINE MALEATE CHEMBL2107339 antagonist ChemblInteractions
ADRA2A 150 ERGOTAMINE TARTRATE CHEMBL2062265 agonist ChemblInteractions
ADRA2A 150 TETRAHYDROZOLINE HYDROCHLORIDE CHEMBL1200413 agonist ChemblInteractions
ADRA2A 150 PHENTOLAMINE MESYLATE CHEMBL1200873 antagonist ChemblInteractions
ADRA2A 150 CLONIDINE HYDROCHLORIDE CHEMBL1705 agonist ChemblInteractions
ADRA2A 150 BETHANIDINE CHEMBL1201260 agonist TdgClinicalTrial, TEND, DrugBank 1962798, 2545383
ADRA2A 150 OLANZAPINE CHEMBL715 antagonist TdgClinicalTrial, DrugBank 17848919
ADRA2A 150 CLOZAPINE CHEMBL42 antagonist DrugBank 17848919
ADRA2A 150 RISPERIDONE CHEMBL85 antagonist DrugBank 15907153, 11132243
ADRA2A 150 YOHIMBINE CHEMBL15245 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 10611634, 10506165, 12591093, 16325800, 17558432, 17664022
ADRA2A 150 PARA-METHOXYAMPHETAMINE CHEMBL278663 agonist DrugBank 17139284, 17016423
ADRA2A 150 DRONEDARONE CHEMBL184412 DrugBank 17389667
ADRA2A 150 LOFEXIDINE CHEMBL17860 agonist TdgClinicalTrial, TEND, DrugBank 1357064, 10598217, 10882840
ADRA2A 150 MIANSERIN CHEMBL6437 antagonist TdgClinicalTrial, TEND, DrugBank 16814817
ADRA2A 150 NAPHAZOLINE CHEMBL761 agonist DrugBank 17852165, 8930173, 11180982
ADRA2A 150 CIRAZOLINE CHEMBL13852 antagonist DrugBank 8564227, 6123592
ADRA2A 150 BRIMONIDINE CHEMBL844 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
ADRA2A 150 BENZPHETAMINE (CHEMBL1201358) CHEMBL1201358 TdgClinicalTrial, TEND
ADRA2A 150 EPINEPHRINE CHEMBL679 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
ADRA2A 150 PERGOLIDE CHEMBL531 agonist GuideToPharmacologyInteractions
ADRA2A 150 N,N-HEXAMETHYLENEAMILORIDE CHEMBL501701 allosteric modulator GuideToPharmacologyInteractions
ADRA2A 150 CHEMBL10332 CHEMBL10332 antagonist GuideToPharmacologyInteractions
ADRA2A 150 TERGURIDE CHEMBL73151 antagonist GuideToPharmacologyInteractions
ADRA2A 150 APRACLONIDINE HYDROCHLORIDE CHEMBL1200379 agonist ChemblInteractions
ADRA2A 150 OXYMETAZOLINE HYDROCHLORIDE CHEMBL1200791 agonist ChemblInteractions
ADRA2A 150 RAUWOLFIA SERPENTINA (CHEMBL3559672) CHEMBL3559672 antagonist ChemblInteractions
ADRA2A 150 DEXMEDETOMIDINE HYDROCHLORIDE CHEMBL2106195 agonist ChemblInteractions
ADRA2A 150 GUANABENZ ACETATE CHEMBL1200560 agonist ChemblInteractions
ADRA2A 150 MIRTAZAPINE CHEMBL654 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank 14628003, 11931344, 12523492, 10793320, 11939713, 11607047
ADRA2A 150 PHENYLPROPANOLAMINE CHEMBL61006 agonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423, 15608085
ADRA2A 150 ERGOLOID MESYLATES CHEMBL2311030 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 2869188
ADRA2A 150 PALIPERIDONE CHEMBL1621 antagonist DrugBank 11132243
ADRA2A 150 LEVOMEPROMAZINE CHEMBL1764 antagonist DrugBank 2870716, 15701205, 6149771
ADRA2A 150 LURASIDONE CHEMBL1237021 antagonist GuideToPharmacologyInteractions, DrugBank 22849428
ADRA2A 150 METHYLDOPA CHEMBL459 agonist TdgClinicalTrial, ChemblInteractions, TEND
ADRA2A 150 DEXMEDETOMIDINE CHEMBL778 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ADRA2A 150 PSEUDOEPHEDRINE CHEMBL1590 TdgClinicalTrial, TEND
ADRA2A 150 GUANFACINE CHEMBL862 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ADRA2A 150 AMPHETAMINE CHEMBL405 TEND
ADRA2A 150 SENREBOTASE CHEMBL3137348 TdgClinicalTrial
ADRA2A 150 FIPAMEZOLE CHEMBL1255582 TdgClinicalTrial
ADRA2A 150 XYLAZINE CHEMBL297362 agonist GuideToPharmacologyInteractions
ADRA2A 150 BROMOCRIPTINE CHEMBL493 antagonist GuideToPharmacologyInteractions
ADRA2A 150 NORADRENALINE CHEMBL1356607 agonist ChemblInteractions
ADRA2A 150 FADOLMIDINE HYDROCHLORIDE CHEMBL2106710 agonist ChemblInteractions
ADRA2A 150 BRIMONIDINE TARTRATE CHEMBL2062257 agonist ChemblInteractions
ADRA2A 150 ALSEROXYLON CHEMBL1201454 antagonist ChemblInteractions
ADRA2A 150 NAPHAZOLINE HYDROCHLORIDE CHEMBL1706 agonist ChemblInteractions
ADRA2A 150 PHENOXYBENZAMINE HYDROCHLORIDE CHEMBL1200787 antagonist ChemblInteractions
ADRA2A 150 METHYLDOPATE HYDROCHLORIDE CHEMBL1200432 agonist ChemblInteractions
ADRA2A 150 TOLAZOLINE HYDROCHLORIDE CHEMBL1689 antagonist ChemblInteractions
ADRA2A 150 TIZANIDINE HYDROCHLORIDE CHEMBL1200329 agonist ChemblInteractions
ADRA2A 150 LEVONORDEFRIN CHEMBL677 agonist ChemblInteractions
ADRA2A 150 CABERGOLINE CHEMBL1201087 antagonist GuideToPharmacologyInteractions, DrugBank 10641988, 18691132, 12388667
ADRA2A 150 ROPINIROLE CHEMBL589 agonist DrugBank 18691132
ADRA2A 150 LOXAPINE CHEMBL831 binder DrugBank
ADRA2A 150 LISURIDE CHEMBL157138 antagonist GuideToPharmacologyInteractions, DrugBank 18691132
ADRA2A 150 ERGOTAMINE CHEMBL442 partial agonist DrugBank 17139284, 17016423, 18066532
ADRA2A 150 FENOLDOPAM CHEMBL588 antagonist TEND, DrugBank 7670737, 17139284, 17016423
ADRA2A 150 APRACLONIDINE CHEMBL647 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 17139284, 17016423, 12630335, 17572343, 15748550, 14575724, 11481271, 16935593, 17824139, 16921219, 20399934
ADRA2A 150 DEBRISOQUIN CHEMBL169901 TdgClinicalTrial, TEND
ADRA2A 150 TIZANIDINE CHEMBL1079 TdgClinicalTrial, TEND
ADRA2A 150 CLONIDINE CHEMBL134 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND
ADRA2A 150 PHENTOLAMINE CHEMBL597 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ADRA2A 150 CHEMBL362051 CHEMBL362051 antagonist GuideToPharmacologyInteractions
ADRA2A 150 CHLORPROMAZINE CHEMBL71 antagonist GuideToPharmacologyInteractions
ADRA2A 150 RAUWOLSCINE CHEMBL10347 antagonist GuideToPharmacologyInteractions
ADRA2A 150 SPIROXATRINE CHEMBL300555 antagonist GuideToPharmacologyInteractions
ADRA2A 150 EPINEPHRINE BITARTRATE CHEMBL1256958 agonist ChemblInteractions
ADRA2A 150 HYDROXYAMPHETAMINE HYDROBROMIDE CHEMBL1200705 agonist ChemblInteractions
ADRA2A 150 ZUCLOPENTHIXOL CHEMBL87385 antagonist DrugBank 12957216
ADRA2A 150 TIAPRIDE CHEMBL84158 antagonist DrugBank 11520476
ADRA2A 150 TOLAZOLINE CHEMBL770 antagonist GuideToPharmacologyInteractions, DrugBank 11938943
ADRA2A 150 GUANABENZ CHEMBL420 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 8263811, 9050980, 15265636, 8819507, 7903385
ADRA2A 150 FLUPIRTINE CHEMBL255044 DrugBank 2901483
ADRA2A 150 ESMIRTAZAPINE CHEMBL1366933 antagonist TdgClinicalTrial, DrugBank 26047892

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
ADRA2A rs1800544 G methylphenidate efficacy yes It is assumed that the alleles are reported in the paper as being on the positive strand. Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. 29230023 1450180291
ADRA2A rs553668 T methylphenidate efficacy no After MPH treatment, no significant associations were found between the change in ARS score (ADHD Rating Scale IV = symptom severity scale) and genotype of the 4 SNPs in this study. Allele T is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G. 23609393 1450376521
ADRA2A rs1800544 C methylphenidate efficacy no After MPH treatment, no significant associations were found between the change in ARS score (ADHD Rating Scale IV = symptom severity scale) and genotype of the 4 SNPs in this study. Allele C is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G. 23609393 1450376527
ADRA2A rs1800544 G methylphenidate efficacy no Clinical Global Impression-Severity (CGI-S) scale and the Children’s Global Assessment Scale (CGAS). Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. 28871191 1450376587
ADRA2A rs1800544 GG methylphenidate efficacy not stated Vanderbilt ADHD Parent Rating Scales and Vanderbilt ADHD Teacher Rating Scales - hyperactive-impulsive domain score was derived by totaling scores from the nine hyperactive-impulsive symptoms. A main effect on hyperactive-impulsive domain scores was detected for the ADRA2A polymorphism ( p = .003), with G homozygotes displaying higher symptom levels on placebo and continuing at these higher levels as MPH doses increased. The ADRA2A-by-dose interaction fell short of the threshold for statistical significance ( p > .025) with a p=0.03. Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CC + CG. 22024001 1450376675
ADRA2A rs1800544 G methylphenidate efficacy no Patients underwent the same naturalistic assessment procedure to evaluate the treatment response, which included the reapplication of the CPRS, CTRS, CGI-S, GAS, CPT and TMT A and B. Treatment responders were defined as follows: patients registering 2 points or greater improvement on the CGI-S and a total GAS score of 60 points or greater (out of 108 subjects 66.6% responded to the treatment, while 33.3% did not). No association for distribution of genotypes according to treatment response. However, multiple logistic regression analysis to examine the relationship between various clinical parameters and treatment response showed that ADRA2A GG genotype (OR=5.6), the presence of a psychiatric comorbidity (OR=5.6) and low SES (OR=2.3) were associated with reduced response to methylphenidate treatment. Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. 27482244 1450376719
ADRA2A rs1800544 GG methylphenidate efficacy not stated Using multiple logistic regression analysis to examine the relationship between various clinical parameters and treatment response showed that ADRA2A GG genotype (OR=5.6), the presence of a psychiatric comorbidity (OR=5.6) and low SES (OR=2.3) were associated with reduced response to methylphenidate treatment. Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity. 27482244 1450376730
ADRA2A rs1800544 G methylphenidate efficacy yes Primary outcome measure was the parent-rated inattentive subscale of the Swanson, Nolan, and Pelham Scale version IV. There was a significant interaction effect between the presence of the G allele and treatment over time for the SNAP-IV inattentive scores during the 3 months of treatment (n = 106; F2,198 = 4.30; P = .02). From baseline to the first and third months of treatment, individuals with the G allele achieved greater reduction of inattentive scores than individuals without this allele p=0.01. Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. 17283289 1450376755
ADRA2A rs1800544 G methylphenidate efficacy no Primary outcome measure was the parent-rated inattentive subscale of the Swanson, Nolan, and Pelham Scale version IV. No effect for the presence of the G allele was detected (n = 106; F1,118 = 0.67; P = .41). No effect of the presence of the G allele was detected (n = 83; F1,81.3 = 0.05; P = .82) for SNAP-IV hyperactive-impulsive scores. Allele G is not associated with response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. 17283289 1450376762
ADRA2A rs1800544 CG + GG methylphenidate efficacy yes In the ANCOVA model considering SNAP-IV baseline inattentive scores as a co- variate, a significant effect of the G allele on SNAP-IV inattentive scores at 4 weeks of treatment [CG=GG genotypes: mean score (SD)=0.673 (0.290); CC genotype: mean score (SD)=0.902 (0.424); n=59; F=6.14; p=0.016] was detected. Genotypes CG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC. 18200436 1450376776
ADRA2A rs1800544 GG methylphenidate efficacy yes ADHD Rating Scale-IV (ARS) and CGI-I are used to analyze response. A “good” response was defined as an improvement from the baseline ARS score after treatment with MPH of >= 50%, and an improvement in the CGI-I score after treatment with MPH of 1 or 2 points, whereas a “poor” response was defined as an improvement in the ARS scores of < 50% and a CGI-I score in the range of 3–7 points. Comparison of the response to MPH treatment between the subjects with and without the ADRA2A G/G genotype revealed that the response to MPH treatment was significantly associated with the G/G genotype. Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CC + CG. 19150055 1450376787
ADRA2A rs553668 G opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele G is not associated with dose of opioids in people with Pain as compared to allele A. 21398039 1449714757
ADRA2A rs553668 AA + AG methylphenidate efficacy no SNAP-IV Swanson, Nolan, and Pelham scale version IV, CGI-S clinical global impression, severity scale are used. Genotypes AA + AG is not associated with response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to genotype GG. 21103886 1450376805
ADRA2A rs1800545 GG atenolol efficacy yes Patients with the GG genotype had a greater change in left ventricular mass between baseline and after 12 weeks of treatment, compared to other genotypes. Genotype GG is associated with increased response to atenolol in people with Hypertrophy, Left Ventricular as compared to genotypes AA + AG. 15614026 982036653
ADRA2A rs1800544 CG + GG clonidine efficacy no This SNP was not selected as a significant predictor of clonidine responsiveness within multiple logistic regression analysis. Responders were defined as those with a 20% decrease in body weight and a 20% increase in urine sodium volume after 3 months of treatment. Genotypes CG + GG are not associated with response to clonidine in people with Liver Cirrhosis as compared to genotype CC. 20833658 982044500
ADRA2A rs1800544 CG + GG methylphenidate efficacy yes Each additional G allele led to a significantly increased change in mean response time variability for the flanker interference task (see the paper for information on this measurement). Increased changes with each additional G allele were also seen for the sustained attention task (see paper), but these did not reach the corrected statistical significance level (p=0.0034). p-values were corrected for baseline ADHD Rating Scale IV (ARS) score, age, sex and IQ. Patients were treated with methylphenidate for 12 weeks. Genotypes CG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC. 23609393 1183699298
ADRA2A rs1800544 CC methylphenidate efficacy yes Positive response defined as Clinical Global Impression-Improvement (CGI-I) rating of 'much improved' or 'very much improved', and decrease in Aberrant Behavior Checklist-Hyperactivity subscale of >25% from baseline. This result was not significant when considering correction for multiple testing (p<0.002). Genotype CC is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotypes CG + GG. 23856854 1184510528
ADRA2A rs1800035 CG + GG dexmedetomidine efficacy yes Patients with the CC genotype had significantly increased pain thresholds and significantly reduced VAS pain scores post-surgery than women with the CG or GG genotypes. There was no significant difference in pain thresholds between genotype group pre-surgery. Genotypes CG + GG are associated with decreased response to dexmedetomidine in women with Pain, Postoperative as compared to genotype CC. 32256718 1451146199
ADRA2A rs775887911 CT + TT dexmedetomidine efficacy yes Patients with the CC genotype had significantly increased pain thresholds and significantly reduced VAS pain scores post-surgery than women with the CT or TT genotypes. There was no significant difference in pain thresholds between genotype group pre-surgery. Genotypes CT + TT are associated with decreased response to dexmedetomidine in women with Pain, Postoperative as compared to genotype CC. 32256718 1451146211
ADRA2A rs201376588 CT + TT dexmedetomidine efficacy yes Patients with the CC genotype had significantly increased pain thresholds and significantly reduced VAS pain scores post-surgery than women with the CT or TT genotypes. There was no significant difference in pain thresholds between genotype group pre-surgery. Genotypes CT + TT are associated with decreased response to dexmedetomidine in women with Pain, Postoperative as compared to genotype CC. 32256718 1451146204
ADRA2A rs1800544 CG Selective serotonin reuptake inhibitors efficacy yes **Please note that this variant was reported by the authors as being in the DRD4 gene. This variant is in the ADRA2A gene according to dbSNP**. A combination of neuroendocrine factors, some clinical characteristics and rs1800544 polymorphisms predicted 74.8% of the SSRI response and 65.5% of SSRI remission. Reported as responders have significantly more CG genotype than non-responders to SSRI therapy. Genotype CG is associated with increased response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes CC + GG. 25642918 1447679358
ADRA2A rs1800544 CC + CG milnacipran efficacy yes depressive symptoms measured on Hamilton Rating Scale for Depression and outcome as change in symptoms, as measured 6 weeks after drug, following 10 days washout. Genotypes CC + CG are associated with increased response to milnacipran in people with Depressive Disorder as compared to genotype GG. 25710119 1447681351
ADRA2A rs1800544 G methylphenidate efficacy no This SNP was significant in initial analysis, but not affirmed in meta-analysis or after correction for multiple testing. This study was conducted in adult patients with ADHD, with treatment success measured by questionnaires filled out by treating physicians. This SNP was the only one of 20 found to be significant in any stage of analysis. Allele G is associated with decreased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to allele C. 27091191 1447983413
ADRA2A rs11195419 C opioids dosage no Variant was significantly associated with opioid dose in the development sample, but lost significance in the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele A. 21398039 1449714090
ADRA2A rs1800545 A opioids dosage no Variant was significantly associated with opioid dose in the development sample, but lost significance in the validation sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714083
ADRA2A rs1800544 CG + GG methylphenidate efficacy no SNAP-IV Swanson, Nolan, and Pelham scale version IV, CGI-S clinical global impression, severity scale are used. Genotypes CG + GG are not associated with response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to genotype CC. 21103886 1450376798
ADRA2A rs1800545 AA + AG methylphenidate efficacy no SNAP-IV Swanson, Nolan, and Pelham scale version IV, CGI-S clinical global impression, severity scale are used. Genotypes AA + AG is not associated with response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to genotype GG. 21103886 1450376812
ADRA2A rs1800544 GG buprenorphine efficacy no Response defined by changes in the rate of dropout from treatment between genotypes. Genotype GG is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to genotypes CC + CG. 29333880 1449271238